anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention discloses a method for constructing plasmodium attenuated sporozoites for expressing an MAGE3 (melanoma-associated antigens 3), an application of the method and an anti-lung-cancer vaccine. The method comprises the following steps: (1) constructing gene knockout plasmids PL0007-UIS+MAGE3 and PL0007-UIS+MAGE3-gfp; and (2) performing gene knockout on plasmodium berghei to obtain recombinant genetic attenuated sporozoites for expressing the MAGE3. The key point for designing an effective cancer vaccine is selection of a carrier which can induce a very strong CD4&lt;+&gt;/CD8&lt;+&gt;T reaction. Most existing vaccines adopt attenuated viruses as carriers, but the effect is not very satisfactory. The invention provides a new thinking for designing a lung cancer vaccine by using plasmodium genetic attenuated sporozoites as carriers. The discussion of functions and mechanisms of TLR2 in resistance of lung cancer by using recombinant genetic attenuated sporozoites which are used for expressing the MAGE3 can provide an important theoretical basis for designing effective subunit vaccines for lung cancer and the like in the future. The thinking of the recombinant genetic attenuated sporozoites in the method disclosed by the invention has an important referential significance for designing effective mycobacterium tuberculosis and HIV vaccines for inducing CD4&lt;+&gt;/CD8&lt;+&gt;T reactions.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an ophthalmic preparation which can give a refreshing feeling over a long time and can refresh tired eyes.  &lt;P&gt;SOLUTION: This ophthalmic preparation comprises a refreshing ingredient and a thickening agent, and has an absolute viscosity of 3 to 15 mPa s at a temperature of 20°C. The refreshing ingredient can include essential oil ingredients (menthol, and the like) and essential oils. The thickening agent can include ethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, dextran, cyclodextrin, and polyoxyethylene polyoxypropylene block copolymer. When such the ophthalmic preparation is applied, the refreshing feeling can be kept over a long time to enhance the compliance of a user.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a cosmetic which has fixability to the body, excellent cleaning properties and is suitable for glossiness and color development.  &lt;P&gt;SOLUTION: The cosmetic comprises particles in which a functional substance is enclosed in a block polymer. The functional substance is a colorant. The cosmetic is a suspension or an emulsion. The average particle diameter of the particles is ≤200 nm and preferably the block polymer has a repeating unit structure of a polyvinyl ether. Preferably the glass transition temperature of at least one segment of the block polymer is ≤0°C. Preferably the cosmetic has irritation responsiveness.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE: To obtain an optically protecting topical composition containing a specific chelating agent and useful for protecting the skin from a harmful effect caused by irradiation of ultraviolet rays such as sunburn, premature aging induced by the sunshine without preventing a sunburn response. CONSTITUTION: This optically protecting topical composition containing chelating agent includes a safe and optically protective amount, preferably 1-10wt.% of the chelating agent having at least 50% inhibiting rate of hydroxy radical formation acting on the iron catalyst in an in vitro solution radical test or having at least 20% reducing rate of the skin wrinkle grade in an in vivo mouth skin wrinkle formation test, and safe and optically effective amount of topical carrier. The chelating agent is represented by an aromatic amine (e.g. 2,2&#39;- dipyridylamine), an aromatic hydroxy acid (e.g. 2,3-dihydroxybenzoic acid), etc. The chelating agent is preferably applied to the skin in 0.001-1.0mg/cm&lt;2&gt; , preferably 0.01-0.1mg/cm&lt;2&gt; .
The invention comprises sulphonated triarylamino-triazines of the formula &lt;FORM:0754071/IV(a)/1&gt; in which all the triazine rings are bound to one another by -NH-R-NH- residues and every ring carbon atom not bound to such a residue is bound to -NH-R-NH2, R representing a residue of the formula Ar or Ar-Z-Ar, in which Ar is an arylene residue substituted by a free or esterified sulphonic acid group and Z is a direct bond or a bridge member, and n representing an integer such that the molecular weight of the compound exceeds 4000, and also salts of these compounds.  The arylene residues may contain further substituents, e.g. methyl groups or additional sulphonic groups, and a single compound may contain different R residues.  The bridge member may be a -C ­ C-, -CH = CH-, -CH2-CH2-, -NH-, -S- or -S-S- group.  The compounds are prepared by reacting a compound of the formula &lt;FORM:0754071/IV(a)/2&gt; in which X is halogen, with one or more diamines of the formula H2N-R-NH2, so that all the X&#39;s enter into reaction, or by reacting intermediates obtainable by the latter reaction with one another or with the starting materials.  The sulphonic acids may be in the form of their salts, and esters, salts and free acids may be converted into one another.  In the Examples: (1) benzidine-2,21-disulphonic acid is neutralized in water with NaOH and is heated with cyanuric chloride at 90 DEG  C.  A mixture of triarylamino-triazines is obtained with average molecular weights of about 30,000 and 420,000.  (2) 4,41-diaminostilbene-2,21-disulphonic acid are similarly reacted with cyanuric chloride, giving a product of average molecular weight 700,000.  (3) The product of Example (2) is reacted with diazomethane to esterify the sulphonic acid groups. The compounds have therapeutic properties.ALSO:Medicaments, especially useful for combating virus diseases, comprise sulphonated triaryl-amino-triazines of the formula &lt;FORM:0754071/VI/1&gt; in which all the trazine rings are bound to one another by -NH-R-NH- residues and every ring carbon atom not bound to such a residue is bound to -NH-R-NH2, and R represents a residue of the formula Ar or Ar-Z-Ar, in which Ar is an arylene residue substituted by free or esterfied sulphonic acid groups and Z is a direct link or a bridge member, the molecular weight over 4,000, and their salts.  The compounds may be made up in the form of tablets, dragees, salves, creams, solutions, suspensions or emulsions for enteral, parenteral or topical administration. Suitable carriers are water, gelatine, lactose, starches, magnesium stearate, talc, vegetable oils, benzyl alcohols, gums, polyalkylene glycols, cholesterol and the material known under the registered Trade Mark &#34;Vaseline.&#34;  The preparations may be sterilised and may contain preserving, stabilizing and wetting agents and salts for regulating osmotic pressure and buffers, and may also contain other therapeutic substances.
PURPOSE:To provide a safe skin/hair cosmetic highly effective for preventing spots, freckles, skin chapping, or sunburn, formulated with an antioxidative active substance extracted from the green leaves of green plants such as barley or wheat. CONSTITUTION:A green plant (in particular, among barley- and wheat-based plants, the fresh stems and/or leaves of a young plant harvested before its date of maturity are esp. suitable) is first squeezed using e.g. a mixer or juicer and, if needed, filtered to remove coarse solid component, preparing a liquor (green liquor). The liquor is then dried into powder which is, in turn, extracted with a sufficient amount of water or n-hexane to obtain an antioxidative active substance, i.e. 2&#39;-o-glycosylisovitexin of the formula. The objective skin/hair cosmetic can be obtained by formulating this substance. This compound of the formula is soluble in both water and alcohols, also excellent in bioabsorbability, and can easily be formulated in skin/hair cosmetics.
The present invention generally relates to systems and method for treating depression, including clinical depression. In one aspect, a subject is engaged in a neurobehavioral task. In some cases, an antidepressant treatment may also be applied to the subject. The neurobehavioral task may be one which tests the ability of the subject to respond to negative feedback and/or commission of an error, and/or to monitor conflicting information or stimuli. For instance, the neurobehavioral task may involve providing a subject with information that is inherently conflicting. In certain embodiments, such treatments may be effective because the neurobehavioral tasks may boost the potential success for treating the depression, e.g., by stimulating the rostral anterior cingulate cortex (&#34;ACC&#34;), and/or by increasing functional or structural connectivity between the ACC and other prefrontal cortex regions, including, but not limited to, the dorsolateral prefrontal cortex. Other aspects of the present invention are directed to systems and methods for implementing such techniques, analyzing such techniques, promotion of such techniques, and the like.
PURPOSE:To provide the titled composition having excellent affinity to living tissue and useful as a dental cement and backing agent, by preparing tricalcium alpha-phosphate powder optionally added with specific amount of the oxide of Zn, Al, etc., and kneading the powder with an aqueous solution containing tannic acid, etc. CONSTITUTION:Calcium alpha-pyrophosphate is mixed with equimolar amount of CaCO3 heated at 1,200 deg.C for 1hr, and quenched to obtain tricalcium alpha-phosphate used as the principal component. The component is added optionally with 0- 13wt% oxide of Zn, Al and/or Mg, calcined at &lt;=1,200 deg.C for 1hr, and pulverized to pass through a 1,500 mesh sieve. The obtained powder is kneaded with an aqueous solution containing one or more compounds slected from tannin, sodium monochlorophosphate, NaCl, and a sodium salt of organic acid. EFFECT:A composition curable in a short time (i.e. within 5-15min) can be produced without using a polyfunctional acrylate compound having various problems.
A process for the preparation of the compound of the formula I and its salts is described. It is based on the reduction of the acid amide of the formula II. The reduction is advantageously carried out using a complex metal hydride. The compound of the formula I forms racemates, the synthesis claimed leading to the optically active components. Under the name phendilin, the final substance is used pharmaceutically against angina pectoris. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and a composition for use in perfusion application.  &lt;P&gt;SOLUTION: At least two liquid compositions are infused, perfused and/or transfused into a subject or its derivative, such as an isolated organ or tissue. The first liquid composition is a plasma-like solution which does not contain a non-natural biological buffer liquid and also the second liquid composition is a liquid blood composition. Preferably, an additional amount of the first solution or its derivative is administered to a patient and thereafter the liquid blood composition is introduced. A kit and a system for carrying out the method are also provided. Then, the method and the composition are used in application of various kinds of perfusion containing treatments in hypothermic surgical applications, cold storage procedures, and the like.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
FIELD: medicine. SUBSTANCE: one should carry out extraction of reduced larch wood with aqueous solution of organic solvent, solvent&#39;s distillation and recrystallization of aqueous-phase precipitated residue. After recrystallization obtained product should be dissolved in aqueous solution of ethanol at heating, then obtained solution should be cooled up to 10 C, not higher. Precipitated residue should be filtered followed by repeated recrystallization in the mixture of acetonitril and aqueous solution of acetic acid. EFFECT: improved ecological value. 2 cl, 1 ex
The present invention relates to kits and methods for efficiently generating 5&#39; capped RNA having a modified cap nucleotide and for use of such modified-nucleotide-capped RNA molecules. The invention is used to obtain novel compositions of such modified- nucleotide-capped RNA molecules. In particular, the present invention provides kits and methods for capping RNA using a modified cap nucleotide and a capping enzyme system, such as poxvirus capping enzyme. The present invention finds use for in vitro production o 5&#39;-capped RNA having a modified cap nucleotide and for in vitro or in vivo production o polypeptides by in vitro or in vivo translation of such modified-nucleotide-capped RNA for a variety of research, therapeutic, and commercial applications. The invention also provides methods and kits for capturing or isolating uncapped RNA comprising primary RNA transcripts or RNA having a 5&#39;-diphosphate, such as RNA synthesized in vitro or obtained from a biological source, including prokaryotic mRNA that is in a mixture with other prokaryotic and/or eukaryotic nucleic acids. The method for capturing modified-nucleotide- capped RNA also provides methods and kits for obtaining only type-specific or condition- specific modified-nucleotide-capped RNA by cap-dependent subtraction of that portion of the captured modified-nucleotide-capped RNA in cells of one type or condition that is the same as RNA in cells of another type or condition. The invention further provides methods and kits for using a capping enzyme system and modified cap nucleotides for labelin uncapped RNA comprising primary RNA transcripts or RNA having a 5 &#39;-diphosphate with detectable dye or enzyme moieties.
PROBLEM TO BE SOLVED: To obtain a novel drug delivery agent of which the capability for accumulating a drug at an objective site can be enhanced by the change in temp. by forming a block copolymer having a polymer block comprising repeating acrylamide deriv. units and a polymer block comprising specific repeating units. SOLUTION: For instance, a polymer having functional group at its one molecular end and represented by formula III [wherein A is a chain comprising repeating acrylamide deriv. units represented by formula I (wherein R&lt;1&gt; and R&lt;2&gt; are each H or an alkyl; and (m) is an integer of 5-500); and X is an alkyl or phenyl group substd. by an amino or carboxyl group, etc.] is reacted with a polymer having a functional group at its one molecular end and represented by formula IV  wherein B is a chain comprising repeating units represented by formula II [wherein R&lt;3&gt; is H, a halogen, or a lower alkyl;  Z is an optionally substd. phenyl group, a lower alkyl, an alkoxy, cyano, or a COOR&lt;4&gt; (wherein R&lt;4&gt; is H or a hydrocarbon group); and (n) is an integer of 1-500]; and Y is a substd. alkyl or phenyl} to give an AB-type block copolymer having a polymer block comprising repeating units represented by formula I and a polymer block comprising repeating units represented by formula II.
The invention discloses application of a Stat3 signal pathway inhibitor Static in treating an obesity phenotype caused by glucocorticoid. Glucocorticoids disrupt the mouse&#39;s intestinal proliferative apoptotic balance, leading to intestinal growth, and increase nutrient absorption, resulting in obesity. The drug Static is an inhibitor of Stat3 protein phosphorylation and dimerization, and directly inhibits activation of downstream signaling pathways of Stat 3. The expression of liver Fgf21 is regulated by Stat3, and the proliferation and apoptosis balance of intestinal tracts are influenced. In particular, the invention relates to Static inhibiting the expression of Stat3 gene or protein, inhibiting the growth of intestinal tract, reducing the absorption of nutrient substances and thus inhibiting the occurrence of obesity. Therefore, static can be used as a novel weight-losing drug of glucocorticoid obesity.
PROBLEM TO BE SOLVED: To obtain the subject new compound capable of improving insulin resistance which is a cause of hyperlipemia and non-insulin dependent diabetes mellitus, having high safety and useful as an effective hypoglycemic agent. SOLUTION: This is a compound expressed by formula I [(n) is 2 or 3], e.g. 5-(2-formylethenyl)-2-methoxy benzoic acid methyl. A compound of formula I is produced by reacting a compound of formula II with a compound of formula III. The reaction is carried out in an organic solvent, e.g. dimethylsulfoxide using a condensing agent, e.g. 1-ethyl-3-(3&#39;-dimethylaminopropyl)carbodiimide and optionally adding an organic base (e.g. triethylamine). The reaction temperature ranges from ice cooling to room temperature.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an electronic medical chart formation/management system for local health care capable of facilitating the creation of an electronic medical chart and attaining the sharing of medical information.  &lt;P&gt;SOLUTION: A doctor of a medical institution 21 performs the remote examination of a home patient through television telephones 23 and 73. A terminal 22 of the medical institution 21 transmits a voice during the examination as voice file data to a sever 12 of an electronic chart center 11 set within a local area including a community such as local government unit or a local medical association through a network 81. The server 12 of the center 11 recognizes the voice file data as a sentence voice to perform text formation processing, and forms, stores and manages an electronic medical chart. The electronic medical chart stored in and managed by the center 11 is accessible from a terminal device of a medical institution or the like registered as a member in the electronic medical chart formation/management system 1.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Capsules having water-soluble nuclei of edible or flavouring matter surrounded by walls of jellied gelatin are formed by causing the water-miscible nucleus materials to replace an oily nucleus originally enclosed in the capsule.  The replacement is effected by immersing the capsules, with the walls in a swollen state due to absorbed water, in a liquid exchange vehicle which is miscible with water and a solvent for the liquid nucleus, and then recovering the capsules from the liquid exchange vehicle and extracting the water from the capsule walls in a water absorbing bath to render them impermeable by the new liquid nucleus.  For example d-limonene disposed in an aqueous solution of gelatin and gum arabic can be encapsulated by cooling the system and lowering its pH.  The capsules can then be filtered and immersed in anhydrous ethanol for one hour, after which the super latent liquid is replaced by a solution of 20% terpene-less lemon oil in ethanol.  After five hours the capsules are filtered and washed in warm ethanol saturated with sorbitol.  The capsules may then be dried with starch or by a fluidized bed.  Other examples describe the replacement of corn oil by edible components dissolved in ethanol, and the replacement of acetylated monoglycerides by a solution of vanillin in ethanol. The new nucleus may consist of the water-miscible fraction of flavours expressed from seeds, leaves, fruits &amp;c.
PROBLEM TO BE SOLVED: To use tramadol in the production of a peroral drug having controlled delivery rate and effective for suppressing medium to severe pain over a specific period or longer. SOLUTION: Tramadol or its pharmacologically permissible salt is used as an active component in an amount of 50-800 mg per unit dose (in terms of tramadol hydrochloride) in the preparation of a peroral drug having controlled delivery rate and useful for suppressing medium to severe pain over &gt;=12 hr. The drug preferably has granular, spherical, multi-particulate or capsule form, etc. An example of the preferable process for the production of the drug comprises the addition of the above active component to a delivery controlling matrix preferably containing one or more kinds of alkyl cellulose (e.g. ethyl cellulose) and one or more kinds of 12-36C aliphatic alcohol (e.g. cetostearyl alcohol).
1,221,447. Uracils. E. I. DU PONT DE NEMOURS &amp; CO. 15 Oct., 1968 [16 Oct., 1967], No. 48770/68. Heading C2C. Sodium and potassium salts of 5-chloro-3,6- disubstituted uracils are prepared by reacting an aqueous solution of the sodium or potassium salt of a 3,6-disubstituted uracil with an aqueous solution of a 0-40% stoichiometric excess of sodium or potassium hypochlorite at a temperature between -10 and +65 C. The free uracils may be obtained by acidification of the salts thus produced. The solution of the starting material may be prepared by the reaction of a substituted urea with a #-keto ester in an aprotic solvent followed by alkaline cyclization of the ureido intermediate, or by reacting a substituted acetoacetamide with an alkyl carbamate followed by cyclization of the intermediate crotonamide.
The microgranules have three concentric layers. The first (interior) layer comprises an inert excipient; the second layer comprises vincamine (deriv.); and the third (external) layer comprises microporous shell of an active excipient. The inert excipient consists of &gt;2 of saccharose, starch, steric acid, lactose and talc. The active excipient comprises &gt;=2 natural and/ or synthetic polymers chosen from gelatin, gum arabic, gum lac, cellulose acetatephthalate, ethyl cellulose, polyoxyethylene glycol, copoly (styrene-acrylonitrile), polymethacrylates and polyvinylpyrrolidone. The microgranules give regular, progressive release of vincamine giving a constant rate of diffusion over long periods, needing admin. only twice a day c.f. 6 times for prior forms.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a bleaching agent containing an unsaturated fatty acid monoglyceride.  &lt;P&gt;SOLUTION: The unsaturated fatty acid monoglyceride comprises any one of three hydroxy groups of glycerol, which is bound with an unsaturated fatty acid by an ester bond. The bleaching agent containing the unsaturated fatty acid monoglyceride exhibits an excellent bleaching action and excellent stability. The unsaturated fatty acid monoglyceride may be extracted from whole or part of plant or prepared by an arbitrary reaction. An unsaturated fatty acid monoglyceride on the market may be used. The bleaching agent is applied to a cosmetic, a quasi-drug or a medicine.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
A prescription for clearing blood, dissolving thrombus and preventing sudden death, belonging to the technical field of human body prevention and health care. It is the regulation of physiological functions of the human body by certain drugs. The blood circulation is not stopped until foreign matters in the blood are dissolved from the source of hematogenesis and the blood circulation is promoted, so that the aim of preventing and treating the sudden cardiac and cerebral death is fulfilled. The prescription is developed aiming at the normal circulation of blood. Indicating a high level of blood abnormality based on the relevant data. Blood abnormalities can lead to failure of the blood to function properly, which can lead to a variety of diseases. The cardiovascular and cerebrovascular diseases are the two most dangerous diseases with the greatest danger. The &#39;blood clearing&#39; in the formula is the treatment principle, and the &#39;thrombolysis&#39; is the treatment principle, so the formula has the advantages of quick response, short time and less medicine consumption, and the formula mainly comprises Chinese herbal medicines, so the formula has wide medicine sources and low toxicity. It embodies the good medical science of the prescription with good curative effect on cardiovascular and cerebrovascular diseases, low price and low drug cost. The product can be applied to the middle-aged and the elderly people regardless of male and female, and has the effects of treating and preventing diseases and prolonging life.